November 29, 2015
Recommended Topic Related To:


"The U.S. Food and Drug Administration is alerting hospitals, health care professionals, and patients of a voluntary recall of all non-expired drug products produced and distributed for sterile use by Abrams Royal Compounding Pharmacy in Dallas, T"...


How Supplied


Subcutaneous Fluid Administration

HYLENEX recombinant (hyaluronidase human injection) is indicated as an adjuvant in subcutaneous fluid administration for achieving hydration.

Dispersion and Absorption of Injected Drugs

HYLENEX recombinant (hyaluronidase human injection) is indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.

Subcutaneous Urography

HYLENEX recombinant (hyaluronidase human injection) is indicated as an adjunct in subcutaneous urography for improving resorption of radiopaque agents.


Always use aseptic precautions. Lightly pinch the skin up into a small mound and insert the needle/catheter into the subcutaneous space. Inject HYLENEX recombinant (hyaluronidase human injection) through the catheter hub or injection port closest to the needle/catheter. Begin administration of solution. Solution should start in readily.

Subcutaneous Fluid Administration

150 U of HYLENEX recombinant (hyaluronidase human injection) injected prior to start of subcutaneous fluid administration, will facilitate absorption of 1,000 mL or more of solution. As with all parenteral fluid therapy, observe effect closely, with the same precautions for restoring fluid and electrolyte balance as in intravenous injections. The dose, the rate of injection, and the type of solution (saline, glucose, Ringer's, etc.) must be adjusted carefully to the individual patient. When solutions devoid of inorganic electrolytes are administered subcutaneously, hypovolemia may occur. This may be prevented by using solutions containing adequate amounts of inorganic electrolytes and/or controlling the volume and speed of administration.

HYLENEX recombinant (hyaluronidase human injection) may be added to small volumes of solution, such as fluid replacement solutions or solutions of drugs for subcutaneous injection. Subcutaneous fluids should be administered as directed by a physician. The dosage of subcutaneous fluids administered is dependent upon the age, weight, and clinical condition of the patient as well as laboratory determinations. The rate and volume of subcutaneous fluid administration should not exceed those employed for intravenous infusion. For premature infants or during the neonatal period, the daily dosage should not exceed 25 mL/kg of body weight, and the rate of administration should not be greater than 2 mL per minute.

Dispersion and Absorption of Injected Drugs

Dispersion and absorption of other injected drugs may be enhanced by adding 50-300 U, most typically 150 U hyaluronidase, to the injection solution.

It is recommended that appropriate references be consulted regarding physical or chemical incompatibilities before adding HYLENEX (hyaluronidase human injection) recombinant to a solution containing another drug.

Subcutaneous Urography

The subcutaneous route of administration of urographic contrast media is indicated when intravenous administration cannot be successfully accomplished, particularly in infants and small children. With the patient prone, 75 U of HYLENEX recombinant (hyaluronidase human injection) is injected subcutaneously over each scapula, followed by injection of the contrast medium at the same sites.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.


Dosage Forms And Strengths

150 USP units/mL single dose vials

Storage And Handling

HYLENEX recombinant (hyaluronidase human injection) is supplied sterile as 150 USP units of nonpreserved recombinant human hyaluronidase per mL in a single-use glass vial.

1 mL Single Dose Vial available in boxes of 4 (NDC 60977-319-03)

Not Recommended for IV Use.

Store unopened in a refrigerator at 2° to 8°C (36° to 46° F).


Marketed by: Baxter Healthcare Corporation, Deerfield, IL 60015 USA. Manufactured for: Halozyme Therapeutics, Inc., San Diego, CA 92121, By Baxter Pharmaceutical Solutions LLC, Bloomington, IN 47403. For Product Inquiry 1 800 ANA DRUG (1-800-262-3784)

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 12/29/2009

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.

Related Drugs
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations